1
The primary composite endpoint was cardiovascular death, myocardial infarction, or stroke.
2
No significant difference was found for the primary composite endpoint in any treatment comparison.
3
The primary endpoint was a composite endpoint of major morbidity and mortality within 12 months.
4
The primary outcome was the composite endpoint of drug discontinuation and dose reduction of drugs taken on admission.
5
The primary endpoint was a composite endpoint of all-cause death or new Q-wave myocardial infarction at two years.
6
The composite endpoint was incident MACE.
7
The primary outcome was a composite endpoint of death or transfer to intensive care unit (ICU).
8
Conclusion: This study addresses the relative efficiency of various methods for assessing clinical trial events comprising the composite endpoint.
9
Objective evidence of reflux was defined as the composite endpoint of positive 24-h pH monitoring or esophagitis on endoscopy.
10
The primary outcome was the 6 month, Food and Drug Administration-approved composite endpoint of rejection, graft failure, or death.
11
However, there are limited data on the prediction of clinical worsening, an important composite endpoint used in PAH therapy trials.
12
The primary composite endpoint will be assessed through locally reported and adjudicated endpoints supplemented by linkage to the Danish national registers.
13
The primary outcome was defined as a composite endpoint of all-cause death, heart failure, cardiac shock, and cardiac arrest during hospitalization.
14
The primary objective was a composite endpoint of treatment-limiting events, incorporating mortality, viral failure, treatment-limiting toxic effects, and adherence to visit schedule.
15
HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint.
16
The primary outcome was major adverse cardiovascular events (MACE) defined as 1-year composite endpoint of cardiac mortality, recurrent MI, revascularization, or stroke.
